TPCW
SNDX icon

TD Private Client Wealth’s Syndax Pharmaceuticals SNDX Stock Holding History

TD Private Client Wealth’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$809 Buy
+37
New +$769 ﹤0.01% 1500
2025
Q3 		– Sell
-54
Closed -$506 – 1564
2025
Q2 		$506 Buy
+54
New +$594 ﹤0.01% 1346

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

TD Private Client Wealth's SNDX Position: Q2 2026 in Review

TD Private Client Wealth opened a new position in Syndax Pharmaceuticals (SNDX) in Q2 2026: 37 shares worth $809. The stake represents ﹤0.01% of the portfolio and ranks #1500 among its holdings. This is a return to the name: TD Private Client Wealth previously reported a position in SNDX as recently as Q2 2025.

TD Private Client Wealth first reported a position in SNDX in Q2 2025 and has held it in 2 quarters since. 243 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • TD Private Client Wealth held 37 shares of Syndax Pharmaceuticals worth $809 as of Q2 2026.
  • Syndax Pharmaceuticals was a new TD Private Client Wealth position in Q2 2026.
  • Syndax Pharmaceuticals made up ﹤0.01% of TD Private Client Wealth's portfolio in Q2 2026, its #1500 holding.
  • TD Private Client Wealth first reported a position in Syndax Pharmaceuticals in Q2 2025 and has held it in 2 quarters since.
  • 243 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on TD Private Client Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.